Texas Capital Bank Wealth Management Services Inc Acquires New Stake in Cue Biopharma, Inc. $CUE

Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Cue Biopharma, Inc. (NASDAQ:CUE) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 22,881 shares of the company’s stock, valued at approximately $722,000. Texas Capital Bank Wealth Management Services Inc owned approximately 0.54% of Cue Biopharma at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. boosted its stake in Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after purchasing an additional 73,000 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Cue Biopharma in the 3rd quarter worth $62,000. Stifel Financial Corp raised its stake in shares of Cue Biopharma by 25.4% in the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after buying an additional 50,000 shares in the last quarter. Boothbay Fund Management LLC raised its stake in shares of Cue Biopharma by 15.3% in the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after buying an additional 93,333 shares in the last quarter. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Cue Biopharma in the second quarter valued at $389,000. 35.04% of the stock is currently owned by institutional investors and hedge funds.

Cue Biopharma Stock Performance

Shares of NASDAQ:CUE opened at $27.64 on Tuesday. The stock has a market capitalization of $116.09 million, a price-to-earnings ratio of -1.02 and a beta of 2.47. Cue Biopharma, Inc. has a 1-year low of $4.97 and a 1-year high of $45.50. The company has a 50 day moving average price of $29.47 and a 200 day moving average price of $143.72.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($22.45). Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 482.58%. The company had revenue of $7.88 million during the quarter, compared to the consensus estimate of $3.00 million.

Insider Buying and Selling

In related news, VP Michael Vincent Meluzio sold 5,628 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $30.09, for a total value of $169,346.52. Following the completion of the transaction, the vice president owned 48,961 shares in the company, valued at $1,473,236.49. This trade represents a 10.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Sumita Ray sold 8,829 shares of Cue Biopharma stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $30.09, for a total value of $265,664.61. Following the completion of the transaction, the insider directly owned 118,545 shares in the company, valued at $3,567,019.05. This represents a 6.93% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 72,715 shares of company stock worth $2,041,555 in the last three months. 14.56% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on CUE shares. Wall Street Zen cut Cue Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cue Biopharma in a research report on Thursday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cue Biopharma has an average rating of “Sell”.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.